Skip to main content
Premium Trial:

Request an Annual Quote

Enzo Posts Strong Q1 Revenue and Income; Exec Hints Trend May Not Last

NEW YORK, Dec. 16 - Enzo Biochem today reported strong first-quarter revenue growth atop an increase in R&D spending and a jump in net income. However, a top executive hinted the results were largely due to "unusually strong"--yet short-lived--demand.

 

Total revenue for the period ended Oct. 31 was $17.4 million compared with $13.4 million one year ago, and R&D spending grew almost 34 percent, to $1.8 million.

 

Still, Enzo managed to post first quarter net income of $3.7 million, or $.13 per share, compared with $1.8 million, or $.06 per share, year over year.

 

The company said it had roughly $73.2 million in cash and cash equivalents as of Oct. 31.

 

However, Enzo President  Barry Weiner cautioned that while the three months ended Oct. 31 amounted to "a quarter of growth" for the company, investors should not "construe" the results as "indicative of what successive future quarters will look like." Still, he stressed the outlook "remains favorable."

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.